Introduction. The objective of this review was to evaluate the published literature on epidemiologic risk factors for epithelial ovarian cancer among women with a diagnosis of endometriosis. Material and methods. A systematic literature search was conducted in PubMed and Scopus. Studies comparing epidemiologic risk factors of epithelial ovarian cancer among women with endometriosis were included. A quality assessment was conducted using the Newcastle-Ottawa Scale. Results. Eight of 794 articles met the inclusion criteria. A lower risk of epithelial ovarian cancer was observed in women with documented complete surgical excision of endometriotic tissue and suggested among women with unilateral oophorectomy. The use of oral contraceptives (≥10 years) may be associated with a lower risk of epithelial ovarian cancer among women with endometriosis, whereas older age at endometriosis diagnosis (≥45 years, pre-or postmenopausal), nulliparity, hyperestrogenism (endogenous or exogenous), premenopausal status at endometriosis diagnosis, solid compartments as well as larger size of endometrioma (≥9 cm in diameter at endometriosis diagnosis) were all associated with an increased risk of ovarian cancer. Conclusions. A subgroup of women with endometriosis characterized by endometriosis observed through surgery or imaging after the age of 45 years, nulliparity, postmenopausal status at endometriosis diagnosis, larger size of endometrioma (>9 cm) at endometriosis diagnosis, hyperestrogenism (endogenous or exogenous) and/or cysts with solid compartments may have an elevated risk of epithelial ovarian cancer. However, due to the limited number and size of studies in this area we cannot draw definitive conclusions. Further research into a risk factor profile among women with endometriosis is needed before clear recommendations can be made.
Introduction
Endometriosis, estimated to affect 6-10% of women of reproductive age and 25-50% of women with infertility, is defined as endometrial-like tissue outside the uterine cavity often associated with pelvic pain and infertility (1) . Endometriosis is a benign disease, although it shares similarities with malignant diseases such as attachment, damage, and invasion of target tissue and local and distant foci formation (2, 3) . Epithelial ovarian cancer (EOC) is the deadliest of all gynecological cancers, often diagnosed beyond cure due to the late onset of symptoms and lack of good screening options (4) (5) (6) . Several histological subtypes (serous, clear cell, endometrioid, and mucinous) exist, which are believed to develop through distinct pathological pathways (7) .
Endometriosis has consistently been associated with an increased risk of developing ovarian clear cell, low-grade serous, and ovarian endometrioid adenocarcinomas (8) (9) (10) (11) (12) . A large pooled analysis among women with a selfreported diagnosis of endometriosis found a 46% increased risk (OR = 1.46; 95% CI 1.31-1.63, p < 0.0001) compared with women without endometriosis. The risk of EOC among women with endometriosis might, however, be higher, because a recent study found a stronger relation with EOC according to the strength of evidence behind the definitive endometriosis diagnosis (verified with histology). This finding suggests an impact of endometriosis misclassification that attenuated the observed association (13) .
There is pathological evidence suggesting that a subtype of endometrioid and clear cell carcinomas may develop from endometriotic precursor lesions within the ovaries (14, 15) . The endometriotic cysts are characterized by cyclic hemorrhage into the cysts leading to accumulation of blood components, for example iron, known to induce inflammation by oxidative stress. This inflammatory microenvironment may cause DNA damage, possibly leading to malignant transformation (16) (17) (18) . Findings of subtype-specific molecular alterations within these tumors and endometriotic precursor lesions support this theory, for example somatic gene mutations in ARID1A, PIK3CA, b-catenin, and PTEN and loss of heterozygosity (19) (20) (21) (22) . Low-grade serous ovarian carcinoma is hypothesized to arise from endosalpingiosis or by shedding of normal fallopian tube epithelium into inclusion cysts at time of ovulation (7, 14, 15) , but the role of this mechanism in endometriosis-related ovarian cancer is unknown. Evidence of the causality between endometriosis and ovarian cancer has not yet been established.
The purpose of this review was to critically review the literature regarding EOC risk factors among women with endometriosis to identify potential subgroups of women with endometriosis at high and/or low risk of EOC (Figure 1 ).
Material and methods
Inclusion criteria were specified before the literature search and constituted retrospective and prospective cohort and case-control studies written in English, Danish, Swedish, or Norwegian and published after 1990 examining any risk factor of developing EOC among women with a diagnosis of ovarian endometrioma, where the primary population of included women constituted women with a diagnosis of endometriosis. The two electronic databases PubMed and Scopus were searched using a detailed search string combining the words: endometriosis, risk factor, epidemiology, complication, clear cell, endometrioid adenocarcinoma, serous, and EOC. The search strategy was prepared in collaboration with two librarians and conducted by one of the authors (LHT) on 9 December 2015. For the detailed search strategy see Appendix S1.
Two investigators independently screened title and abstracts for eligibility; any discrepancies resulted in retrieval of the full text, disagreements among full-text versions were resolved by consensus or by involving a third party. A further analysis of the references cited in included articles and relevant reviews was performed, leading to the inclusion of two additional articles. Study characteristics (design, inclusion period, number of cases and controls, age, diagnosis and location of endometriosis, ovarian cancer histology, statistical analysis and confounding variables) ( Table 1) and risk estimates on all published variables were extracted by two of the authors EOC Endometriosis Endometriosis associated EOC Figure 1 . We wish to compare the risk factor profile among women with endometriosis vs. women with endometriosis associated epithelial ovarian cancer (EOC). [Color figure can be viewed at wileyonlinelibrary.com]
Key Message
A subgroup of women with endometriosis [nulliparous, ≥45 years with visualized endometriosis, or with a large endometrioma (>9 cm)], could be offered increased surveillance for ovarian cancer development. However, more research is needed to make clear recommendations with regards to systematic screening or counseling of this population. and divided into three categories: hormonal, surgical, and other.
The search resulted in a total of 741 articles after removing duplicates. Seventy-nine articles were excluded having been published either before 1990 or in languages other than English, Danish, Swedish, or Norwegian. Of the remaining 662 studies causes for exclusion included reviews and case reports: 133 were neither regarding ovarian cancer nor endometriosis; 158 were only regarding endometriosis or ovarian cancer; 24 were about adenomyosis; 144 described endometriosis (with and without malignant transformation) and cancers in other locations than the ovaries; and 100 articles on endometriosis and ovarian cancer did not examine risk factors). One hundred and three articles were identified for full text review, a detailed description of exclusion criteria can be seen in the Supporting Information (Appendix S2) (one was neither regarding ovarian cancer nor endometriosis, 18 were only regarding endometriosis or ovarian cancer, 76 articles were about endometriosis and ovarian cancer but were not primary research on risk factors including reviews, case reports, published comments, editorials, etc.). In total, eight studies met the inclusion criteria from this literature search ( Figure 2 ).
All included studies were retrospective case-control or cohort studies, relying on databases, interviews or questionnaires. A quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) for nonrandomized studies (23) ( Tables 2 and 3 ). NOS assesses the quality of a case-control study based on selection of cases and controls, comparability of the groups, and the ascertainment of the exposure or outcome of interest and the quality of of a cohort study based on selection of the cohort, comparability on the basis of design/analysis and outcome. For comparability, age was chosen as the most important factor, with oral contraceptive (OC) use, family history of cancer, and gravidity as additional factors. Quantifying response rate, a point was given if response rate among both cases and controls was above ≥60%. Regarding cohort studies an adequate follow-up was defined as ≥10 years among a cohort of women with an average age of ≥40 years. All studies were given a score between 0 and 9 points by two of the investigators. In this systematic review a score of ≥7 points equals a high score (i.e. a high quality in methodology), a score between 4 and 6 was of moderate quality, and 0-3 constituted low quality. Two of the included case-control studies pooled data from two or more previous research articles. In such cases, each individual study was scored, and a total score was given by the lowest common denominator. Other study limitations are described in the Discussion section.
Data published by Rossing et al. (10) were used to calculate the effect of ovarian surgery in relation to the risk of EOC (logistic regression) and when studies were based on the same population of women and variables were coinciding, data from the largest study was used (9, (24) (25) (26) . The diversity and limitations of the included studies did not make it reasonable to conduct a meta-analysis (Table 1) . A descriptive approach was adopted concerning all published risk estimates (odds ratio, standardized Figure 2 . Flowchart of literature search conducted 9 December, 2015. Table 2 . Quality assessment by the Newcastle-Ottawa Scale (NOS); case and control studies.
Author + the feature is present, À the feature is absent. For comparability age was chosen as the most important factor, and oral contraceptives use, family history and gravidity as additional factors.
incidence ratio, and hazard ratio). The PRISMA Statement for systematic reviews was followed (27) .
Results Table 1 summarizes the characteristics of the included  studies, and Tables 2 and 3 show in detail the NOS quality assessment score. For a detailed outline of published data, Tables 4-6 (Table 4) . Regarding age, being ≥49 years at diagnosis of endometriosis was associated with ovarian malignancy (specificity 80.6%; 95% CI 62.5-92.5%, and sensitivity 82.9%; 95% CI 67.9-92.8%) ( Table 4 ). Cyst size, CA 125, body mass index (BMI), ascites, laterality, and symptoms at diagnosis (except weight changes) did not differ between the two groups. Among the subgroup of women, who had an observational period before surgery, larger cyst size was associated with malignancy compared with smaller cyst size (4.2 cm vs. 1.0 cm, p = 0.02) (not shown in Table 4 ).
These findings are in line with the results of a registerbased multicenter cohort study by Kobayashi et al. (29) , which included a total of 6398 Japanese women with a diagnosis of ovarian endometrioma. At the time of endometriosis diagnosis, older age (<44 years vs. ≥45 years) (HR 8.12; 95% CI 5.21-11.7), postmenopausal status (HR 8.68; 95% CI 5.01-12.8), and greater diameter (<9 cm vs. ≥9 cm) of endometrioma (HR 13.5; 95% CI 8.98-19.3) were all associated with a significant increased risk of EOC (Table 4) . Interestingly, the incidence of EOC was 0%, 35%, and 65% in women with ovarian endometrioma <6, 6-9, and ≥9 cm in diameter, respectively. This study also found a trend towards increased risk of EOC among nulliparous women (HR 2.17; 95% CI 1.28-3.49, p = 0.212) ( Table 4) . No significant association between marital status, use of hormones (users vs. nonusers; not stratifying on type i.e. unopposed estrogen, estrogen-progesterone combination) (Table 6 ), family history of cancer, or current or previous smoking history at diagnosis of ovarian endometrioma and ovarian cancer were observed.
In a Swedish register-based study, Melin et al. found unilateral oophorectomy or complete extirpation of endometriotic tissue (regardless of location in the pelvic region) to have a strong protective effect on the risk of + the feature is present, À the feature is absent. For comparability age was chosen as the most important factor, and oral contraceptives use, family history and gravidity as additional factors.
EOC (OR 0.10; 95% CI 0.03-0.36 and OR 0.29; 95% CI 0.10-0.84, respectively) ( Table 5 ) (26). Regarding unilateral oophorectomy, a numbers-needed-to-treat analysis showed that 62 women would have to go through the surgical procedure to prevent one case of ovarian cancer. Hormonal treatment was not associated with EOC risk in this study (Table 5) . In a very small study by Rossing et al. (10) the association between ovarian surgery (10 cases/20 controls) and EOC (OR 0.69; 95% CI 0.30-1.59, p = 0.19) was not significant (Table 5) .
Melin et al. (9) included 64 492 women with a first time hospital discharge diagnosis of endometriosis, of whom 122 were diagnosed with ovarian cancer. They found a lower standard incidence ratio (SIR) for the development of ovarian cancer among women, who had a hysterectomy at the time of or before the diagnosis of endometriosis (SIR 1.05; 95% CI 0.63-1.64), compared with women who did not (SIR 1.54; 95% CI 1.25-1.86) ( Table 5 ). It was unclear whether the corresponding women never had a hysterectomy or could have had a hysterectomy after receiving the diagnosis of endometriosis.
Modugno et al. (24) pooled data from four US population-based case-control studies (30) (31) (32) (33) . Data were stratified on endometriosis and adjusted for age, parity, OC use, tubal ligation, family history of ovarian cancer, and study site. Associations, although nonsignificant, between tubal ligation (no vs. yes) or hysterectomy (no vs. yes) and the risk of developing ovarian cancer were observed with an OR of 0.7 (95% CI 0.41-1.25) and 0.69 (95% CI 0.38-1.24), respectively. Furthermore, a significant inverse association between OC use (ever vs. never users) and risk of ovarian cancer was found with an OR of 0.58 (95% CI 0.33-1.03) for <10 years of contraceptive use and an OR of 0.21 (95% CI 0.08-0.58) for ≥10 years of contraceptive use) ( Table 6 ). The strength of the inverse association significantly increased with the number of years of contraceptive use (p-value for trend = 0.003). Furthermore, a significant trend was seen for number of births (p < 0.001), with a decrease in the risk of ovarian cancer with an increasing number of childbirths: OR 0.31 (95% CI 0.18-0.54) for 1-2 births and OR 0.22 (95% CI 0.11-0.45) for ≥3 births, compared with nulliparous women (Table 4 ).
In the small study by Cottreau et al. (25) -using data pooled from two case-control studies (31, 34) -the use of Danazol showed an increased risk of ovarian cancer with an OR of 2.9 (95% CI 1.0-8.5) ( Table 6) . No associations between the use of leuprolide/nafarelin (9 cases/8 controls), OC use, hysterectomy, or infertility drug use and risk of EOC were observed (Tables 5 and 6 ). However, factors indicating selection of Danazol vs. these other treatments were not evaluated.
The study by Zanetta et al. (35) included women with histologically verified cancer anywhere in the pelvic region (i.e. not only restricted to ovarian cancer) arising in close physical proximity to the histologically verified endometriotic lesions, compared with age-matched women with endometriosis without a cancer diagnosis. Cancer locations were: ovaries (15 cases; 48.4%), serosa of the bowel (five cases; 16.1%), cul-de-sac (four cases; 12.9%), or other locations (seven cases; 22.6%). Women who were either obese (BMI > 27 kg/m 2 ) or who had (Table 5 ). Furthermore, a trend towards a greater risk was observed among users of unopposed estrogen and a BMI > 27 (Table 6 ). No significant relation between menopausal status, parity, smoking, history of endometriosis, personal history of cancer, previous treatments with hormones or surgery and the risk of EOC were observed (some are shown in Tables 4 and 6 ). None of the analyses adjusted for potential confounding.
Discussion
To our knowledge, this systematic review is the first summary of available data regarding risk factors for EOC among women with endometriosis. Despite a systematic identification of pertinent publications and wide inclusion criteria, only eight studies met the inclusion criteria. In addition, most of the studies were based on small numbers of cases and controls (Table 1) , which are prone to type two errors yielding insignificant and inconclusive results. Finally, four of eight studies (10, 24, 25, 29) relied on self-reported or clinically verified/non-surgical diagnosis of endometriosis, both of which may be highly impacted by misclassification (36) . Four studies (9, 26, 28, 35) included (mainly) surgical diagnosis of endometriosis (Table 1 ), but could be temporally impacted by incidental observation of endometriosis concurrent with ovarian cancer discovery.
Despite our initial goals, the small number of eligible published studies made it untenable to exclude publications based on study size or endometriosis location, and also resulted in inclusion of studies where the primary goal was not to evaluate risk factors among women with endometriosis or studies that did not distinguish between subtypes of ovarian cancer (Table 1) . However, the number of non-EOC in these studies are few. We therefore consider this misclassification of minor importance. The above described aspects limit clear conclusions from this review. This being said, the study provides important information regarding risk factors of EOC among women with endometriosis, which is of interest in a clinical setting.
The average score of the studies according to the NOS was 7 for the two cohort studies and 6.66 for the six case-control studies (Tables 2 and 3) , indicating a high quality/low risk of bias in methodology of the included cohort studies and a moderate quality/moderate risk of bias of the included case-control studies. None of the studies reached a maximum of 9 stars, indicating the results could be affected by bias. As the studies did not examine the same risk factors it was not feasible to conduct a sub-analysis on the studies with a high NOS score (≥7) evaluating the reliability of our results.
Two included studies investigated the role of age and found a significant predictive correlation between older age (≥45 years and >49 years, respectively) at diagnosis of endometriomas and the risk of ovarian cancer (28, 29) ( Table 4) . A recent retrospective Taiwanese cohort study by Wang et al. (37) found an increase in incidence rate of EOC with advancing age among women with and without a diagnosis of endometriosis (surgically-pathologically verified). Interestingly, a significant increased risk of EOC among women with endometriosis aged <30 or ≥50 years was found when comparing the incidence rate of EOC with age-matched controls without endometriosis (HR 9.63, 95% CI 3.27-28.37 and HR 4.97, 95% CI 1.03-24.09), respectively). Several studies have shown that endometriosis-associated cancers develop at younger ages, although the risk still appears to be extremely low especially for younger women with endometriosis (age <45) (9, 38, 39) . This is supported by Er zen et al. who found a higher percentage of ovarian cancer arising in ovarian endometriosis among women >50 years of age compared with younger women (40) . The genetic precancerous mutations within endometriotic lesions, most likely caused by continuous inflammation in the microenvironment combined with the increased gonadotropin levels, could make perimenopausal women with endometriosis susceptible to EOC earlier in life, explaining why some women with endometriosis may be younger at ovarian cancer diagnosis.
Only one of three studies found a significant association between postmenopausal status and ovarian cancer; however, this study did not adjust for age, leaving the possibility that the increased risk could be a function of age and not menopause (28, 29, 35) (Table 4) .
A diagnosis of endometriosis among postmenopausal women is rare due to reduced endogenous estrogen levels and thereby a decrease in symptoms (41, 42) . Endometriosis is an enigmatic disease where the severity of symptoms and the extent of disease based on surgical visualization (rASRM staging system) are not necessarily related (43) . Furthermore, there is a well-known diagnostic delay for women with endometriosis (44). Hence, older age at endometriosis diagnosis is not necessarily equivalent with late onset of endometriosis nor does it enable us to draw any conclusions with regards to severity of symptoms or disease stage of endometriosis and risk of EOC.
Among the general population, postmenopausal women have a twofold increased risk of ovarian cancer with a peak incidence after menopause (45, 46) . One theory suggests that the elevated level of gonadotropins possibly stimulates, and thereby leads to, the development of ovarian cancer (47, 48) . A theory behind the observed increased risk of ovarian cancer with older age and menopause among women with a diagnosis of endometriosis may be explained by the fact that women diagnosed with endometriosis late in life have not had any previous treatment aimed at reducing symptoms by reducing endometriotic activity and thereby impacting the inflammatory microenvironment. Alternatively, women diagnosed with late-onset endometriosis may indeed represent a subgroup who have a greater risk of malignant transformation because the natural course of endometriosis is regression rather than progression after the menopause.
In summation, older age or menopausal status at endometriosis diagnosis may be suggestive of an increased risk of malignancy. Therefore, close monitoring of women with a late diagnosis of endometriosis, as well as women with continuous signs or symptoms of endometriosis after menopause, may be considered.
Three studies investigated the association between parity and ovarian cancer among women with endometriosis (24, 29, 35) . Two studies (24, 35) found a protective effect with increasing number of childbirths although only one reached a significant level (24) ( Table 4) .
Endometriosis is associated with infertility, though causality has not been established. The etiology may be multifactorial, including altered inflammatory environment, anatomical abnormalities, immunologic, hormonal and genetic aspects (41, (49) (50) (51) (52) . In a cohort of women seeking treatment for infertility, Brinton et al. found that women with endometriosis had the highest risk of developing ovarian cancer (SIR 2.48; 95% CI 1.3-4.2) compared with the general population of women. This estimate was strengthened when analyses were restricted to women with endometriosis and primary infertility (SIR 4.19; 95% CI 2.0-7.7), whereas the risk of EOC among women with endometriosis, who had conceived a child previously, was similar to that in the general population (SIR 1.05; 95% CI 0.2-3.1) (53). Additionally, Stewart et al. found that women with endometriosis had an increased risk of ovarian cancer (HR 2.33; 95% CI 1.02-5.35) compared with women without endometriosis in a cohort of women seeking fertility treatment. Among women with endometriosis who remained childless, this risk was increased threefold (HR 3.11; 95% CI 1.13-8.57), whereas women with endometriosis who succeeded in conceiving a child had a lower and not significantly increased risk of EOC (HR 1.52; 95% CI 0.34-6.75) (54). These findings, supported by Ness et al. (55) , underpin a link between endometriosis, infertility, and ovarian cancer, suggesting that nulliparous women with endometriosis have an elevated risk of developing ovarian cancer.
When assessing the risk of malignancy after the discovery of an ovarian cyst in an outpatient setting, it is recommended to use the 'Risk of Malignancy Index' (RMI), where imaging plays an important role, along with menopausal status and CA 125 (56, 57) . Ultrasonographic findings of solid components in an ovarian cyst, symptomatic or not, are known to strongly indicate malignancy among the general population of women (58, 59) . The study by Kadan et al. confirms that this also applies for women with endometriomas (28) ( Table 4) .
None of the reviewed studies found a statistically significant effect of hysterectomy and sterilization on the risk of EOC among women with endometriosis (Table 5 ) (9, (24) (25) (26) . A hypothesis could be that endometriosis has already caused cellular damage initiating the inflammatory response leading to malignant transformation, making potential prevention (hysterectomy or tubal ligation implied) of further endometriotic implantation futile.
However, hysterectomy and tubal ligation (especially before the age of 35 years) have in some, albeit not all, previous studies been shown to be protective interventions of EOC among the general population (60) (61) (62) (63) . The effect of hysterectomy (on nonmalignant indication), or of tubal ligation in relation to women with endometriosis, may be reduction in the development of new endometriotic foci in premenopausal women by blocking retrograde menstrual flow, a reduction of the blood supply to the ovaries thereby reducing estrogen production and/or a reduction of anti-MUC-1 antibodies due to tubal ligation (61, 64) .
Two studies investigated the relation between complete surgical extirpation of endometriosis and the risk of EOC. Zanetta et al. did not find a significant association (35) ; however, the largest and best designed study found a significant correlation between complete excision of endometriosis, or unilateral oophorectomy, and a lower risk of EOC (26) . Two smaller studies investigating the effect of ovarian surgery and the risk of EOC found no significant association (10, 35) (Table 5) .
Interestingly, excision of endometriosis located in extra-ovarian pelvic areas also seems to decrease the risk of ovarian cancer (26) . This diminishes the strength of the data suggesting that EOC is the result of malignant transformation of only ovarian endometriomas. However, radical excision of endometriosis in the pelvic region can be difficult and carries the risk of severe complications, and it does not reduce the risk of small (microscopic) foci to be overlooked nor does it prevent possible recurrence of endometriosis.
Full laparoscopic excision of an endometrioma, including the cyst wall, has shown significant benefits regarding endometrioma recurrence, reduced risk of recurrent dysmenorrhea, dyspareunia, non-menstrual pelvic pain, and further surgical requirements in the future (65, 66) . Surgical intervention may also reduce the cancer risk, as removal of all visible endometriotic foci possibly decreases the risk of malignant transformation (67) (68) (69) . Furthermore, extensive surgery may reduce the inflammatory responses and level of mediators known to be involved in the development of ovarian cancer (70, 71) .
Results are conflicting regarding surgery of endometriosis and the risk of EOC, making a clear conclusion or recommendation impossible. The risks of radical surgery should be weighed against the benefits in terms of a possible lowered risk of malignant transformation and the decrease in the woman's symptoms before an operative procedure.
Two studies, including the best designed study, did not find a significant association between exogenous hyperestrogenism (hormone replacement therapy) and EOC among women with endometriosis (26, 35) . Regarding endogenous hyperestrogenism (high BMI) Kadan et al. and Zanetta et al. found no significant association in relation to ovarian cancer risk (28, 35) (Table 6 ). However, after pooling women with unopposed estrogen (hormone replacement therapy) or BMI > 27 kg/m 2 , Zanetta et al. found a significant increase in risk of ovarian cancer (Table 6) .
Unopposed estrogen is thought to stimulate endometriotic growth -and maybe recurrence or reactivation of endometriotic foci after surgery (72-74) -causing hyperplasia, atypical endometriosis and, at worst, leading to malignant transformation (75, 76) . Estrogen has shown EOC cell growth stimulation and higher invasion rates after estrogen application in vitro (77) . Known risk factors for the development of ovarian cancer among the general population of women is associated with high levels of estrogen such as long menstrual life span, early age at menarche, late age at menopause (78) (79) (80) (81) and use of HRT with estrogen-only substitution (82) (83) (84) .
Three studies [not counting Cottreau et al. (25) because of the coinciding study population with Modugno et al. (24) ], investigated the effect of OC use among women with endometriosis. Only one found a significant association (24, 26, 35) . The discrepancy may result from differences in the cut-off point (Table 6) ; as the effect of OCs may be related to long-term usage. Indeed the study by Modugno et al. compared <10 years vs. ≥10 years of OC use, whereas the cut-offs in the other studies were shorter. In the study by Kobayashi et al. the use of hormones (yes vs. no) was examined. Due to few hormone users in the case and the control groups (seven estrogen-progesterone users) the result was difficult to interpret (29) .
Oral contraceptive use and pregnancy, especially longterm use (>10 years) and increasing number of childbirths, respectively, are both known protectors of ovarian cancer among women in the general population (85) (86) (87) (88) . Continuous OC use is often a first-line treatment in endometriosis, reducing pain and, possibly, further progression (89) .
The use of OCs and pregnancy lead to reduced ovulatory cycles contributing to the "incessant ovulatory theory" described above. Pregnancy suppresses gonadotropin levels, increases estrogen and progesterone levels, and stops the possible retrograde transportation of exogenous substances through the fallopian tube (7, 90) . Progesterone is hypothesized to be protective of ovarian cancer by reducing gonadotropin and androgen levels, which is in alignment with the observation that progesterone-only OCs also seem to be protective of ovarian cancer (91) .
Androgens may result in the malignant transformation of ovarian surface epithelium cells as they have been shown to stimulate growth (92) . The very small sample size in the study by Cottreau et al. (13 cases/5 controls) does not enable us to justify any conclusion based on the borderline increased risk of ovarian cancer (25) , and Melin et al. found no significant association between Danazol use and EOC (26) . Moreover, in clinical practice Danazol has now largely been replaced by medical therapies with more favorable adverse effects (Table 5) .
In summary, risk factors for the development of EOC among women with endometriosis seem to include older age at the time of diagnosis of endometriosis (≥45 years or ≥49 years) (28, 29) , cysts with solid compartments (28) , postmenopausal status at the time of diagnosis of endometriosis (29) , larger size of endometrioma (≥9 cm) at the time of diagnosis of endometriosis (29) , nulliparity, and hyperestrogenism (endogenous and/or exogenous) (35) . Use of OCs may be preventive of EOC among women with endometriosis, although a significant association was observed in only one study, as was a protective effect of greater parity (24) . One study found a significant protective effect of surgical intervention with unilateral oophorectomy and/or macroscopically complete excision of endometriosis, including foci in other locations than the ovaries (26). Kadan et al. found a low-risk group of ovarian malignancy among women who were under 49 years, had CA 125 <43 U/mL, cysts without solid compartments, and cyst size <11 cm (OR 0; 95% CI 0-0.46, p = 0.008).
Conclusion
A subgroup of women characterized by a diagnosis of endometriosis after the age of 45 years, nulliparity, postmenopausal status, larger size of endometrioma (>9 cm), hyperestrogenism (endogenous or exogenous) and/or cysts with solid compartments at the time of diagnosis may have an elevated risk of EOC, though this subgroup has yet to be identified clearly.
It is possible that this subgroup should be offered regular screenings with CA 125 and ultrasound. However, the limited number of published studies, the small study sample sizes herein and the different study designs do not allow us to draw definitive conclusions and consequent recommendations. Further robust and larger studies are needed to confirm whether these initial findings are truly significant in women with endometriosis (93) (94) (95) (96) .
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